- Recruiting
NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release
Updated: Sep 8, 2022
NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

The purpose of this study is to evaluate the efficacy and safety of cilta-cel out-of-specification (OOS).
Sponsor
Janssen Scientific Affairs, LLC
ClinicalTrials.gov Identifier: NCT05347485
Official Title: A Safety and Efficacy Study of JNJ-68284528 (Ciltacabtagene Autoleucel) Out-of-Specification (OOS) for Commercial Release in Patients With Multiple Myeloma
First Posted: April 26, 2022
Click here for details on ClinicalTrials.gov